MODULATION OF SECRETORY PROCESSES OF PHAGOCYTES BY IX 207-887

In chronic inflammation, the mediators released by phagocytes are in p art responsible for the initiation and perpetuation of the disease. IX 207-887, which is a novel antiarthritic drug, inhibits the release of cytokines from mononuclear cells at concentrations which are achieved therapeutically in human rheumatoid arthritis and in animal models of arthritis. Furthermore, the production of superoxide and release of a zurophil and specific granules by N-formyl-Met-Leu-Phe-stimulated neut rophils are significantly reduced. As a consequence, IX 207-887 may br eak the vicious circle which is manifest in chronic inflammation. In a recent double-blind placebo controlled study IX 207-887 has been show n to be an effective slow-acting drug for use in rheumatoid arthritis.